David Dansie, DO
Family Medicine · Rock Springs, WYNPI 1184889982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $451, 2.5 times the $181 reported in 2019.
Across 76 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$199
- GSK$195
- Amgen$139
- Merck$125
- Lilly USA, LLC$122
- Otsuka America Pharmaceutical, Inc.$99
- plus $406 from 11 others
What the payments were for
- Food & beverage$1,24597%
- Education$403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $199 |
| GSK | 12 | $195 |
| Amgen | 8 | $139 |
| Merck | 8 | $125 |
| Lilly USA, LLC | 8 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Lundbeck LLC | 4 | $79 |
| AstraZeneca | 4 | $62 |
| AbbVie | 2 | $59 |
| Johnson & Johnson | 3 | $51 |
| Novo Nordisk | 2 | $30 |
| Corium, LLC | 1 | $26 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
How this compares
$1,284 in reported general payments places this provider in the 85th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $83,314 |
| RexultiBrexpiprazole | 27 | $39,622 |
| XareltoRivaroxaban | 27 | $22,776 |
| OzempicSemaglutide | 12 | $19,847 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 76 | $19,627 |
| MounjaroTirzepatide | 16 | $16,150 |
| JardianceEmpagliflozin | 24 | $14,342 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,673 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $11,968 |
| JanuviaSitagliptin Phosphate | 15 | $11,712 |
| FarxigaDapagliflozin Propanediol | 13 | $11,473 |
| TradjentaLinagliptin | 18 | $8,757 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,615 |
| Aripiprazole | 30 | $7,075 |
| Fentanyl | 41 | $6,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $199 | $83,314136 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $39,62227 claims |
| Johnson & JohnsonXarelto | $51 | $22,77627 claims |
| Novo NordiskOzempic | $30 | $19,84712 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $62 | $19,08825 claims |
| Lilly USA, LLCMounjaro | $122 | $16,15016 claims |
| GSKTrelegy Ellipta | $195 | $13,67320 claims |
| MerckJanuvia | $125 | $11,71215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Rock Springs
- Jacob JohnsonRock Springs$5K
- Lawrence LauridsenRock Springs$4K
- Brytton LongRock Springs$3K
- Melinda PoyerRock Springs$2K
- Michael BowersRock Springs$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.